95 related articles for article (PubMed ID: 12208754)
21. [The effect of topoisomerase II inhibitor, vepesid, on binding of doxorubicin with DNA in tumor cells sensitive to anthracycline].
Bogush TA; Chmutin EF; Syrkin AB
Biull Eksp Biol Med; 1997 Jan; 123(1):87-90. PubMed ID: 9213469
[No Abstract] [Full Text] [Related]
22. [The proteasome and malignant hemopathies].
Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Bureau JP
Morphologie; 2000 Jun; 84(265):39-43. PubMed ID: 11048297
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon.
Bose S; Stratford FL; Broadfoot KI; Mason GG; Rivett AJ
Biochem J; 2004 Feb; 378(Pt 1):177-84. PubMed ID: 14583091
[TBL] [Abstract][Full Text] [Related]
25. Changes in proteasome localization during the cell cycle.
Palmer A; Mason GG; Paramio JM; Knecht E; Rivett AJ
Eur J Cell Biol; 1994 Jun; 64(1):163-75. PubMed ID: 7957305
[TBL] [Abstract][Full Text] [Related]
26. Cellular response to etoposide treatment.
Montecucco A; Biamonti G
Cancer Lett; 2007 Jul; 252(1):9-18. PubMed ID: 17166655
[TBL] [Abstract][Full Text] [Related]
27. Nuclear entry of poliovirus protease-polymerase precursor 3CD: implications for host cell transcription shut-off.
Sharma R; Raychaudhuri S; Dasgupta A
Virology; 2004 Mar; 320(2):195-205. PubMed ID: 15016543
[TBL] [Abstract][Full Text] [Related]
28. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.
Bardeleben RV; Dunkern T; Kaina B; Fritz G
Int J Mol Med; 2002 Oct; 10(4):473-9. PubMed ID: 12239596
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
30. Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator.
Hwang JH; Kim JY; Cha MR; Ryoo IJ; Choo SJ; Cho SM; Tsukumo Y; Tomida A; Shin-Ya K; Hwang YI; Yoo ID; Park HR
J Cell Physiol; 2008 Apr; 215(1):243-50. PubMed ID: 17941090
[TBL] [Abstract][Full Text] [Related]
31. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
34. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
35. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
Dou QP; Smith DM; Daniel KG; Kazi A
Prog Cell Cycle Res; 2003; 5():441-6. PubMed ID: 14593738
[TBL] [Abstract][Full Text] [Related]
36. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor).
Chen Y; Su YH; Wang CH; Wu JM; Chen JC; Tseng SH
Anticancer Res; 2005; 25(6B):4203-8. PubMed ID: 16309217
[TBL] [Abstract][Full Text] [Related]
38. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells.
Li Z; Arnaud L; Rockwell P; Figueiredo-Pereira ME
J Neurochem; 2004 Jul; 90(1):19-28. PubMed ID: 15198663
[TBL] [Abstract][Full Text] [Related]
39. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.
Ceruti S; Mazzola A; Abbracchio MP
J Pharmacol Exp Ther; 2006 Dec; 319(3):1424-34. PubMed ID: 16971507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
